Literature DB >> 15578093

Novel APC-like properties of human NK cells directly regulate T cell activation.

Jacob Hanna1, Tsufit Gonen-Gross, Jonathan Fitchett, Tony Rowe, Mark Daniels, Tal I Arnon, Roi Gazit, Aviva Joseph, Karoline W Schjetne, Alexander Steinle, Angel Porgador, Dror Mevorach, Debra Goldman-Wohl, Simcha Yagel, Michael J LaBarre, Jane H Buckner, Ofer Mandelboim.   

Abstract

Initiation of the adaptive immune response is dependent on the priming of naive T cells by APCs. Proteomic analysis of unactivated and activated human NK cell membrane-enriched fractions demonstrated that activated NK cells can efficiently stimulate T cells, since they upregulate MHC class II molecules and multiple ligands for TCR costimulatory molecules. Furthermore, by manipulating antigen administration, we show that NK cells possess multiple independent unique pathways for antigen uptake. These results highlight NK cell-mediated cytotoxicity and specific ligand recognition by cell surface-activating receptors on NK cells as unique mechanisms for antigen capturing and presentation. In addition, we analyzed the T cell-activating potential of human NK cells derived from different clinical conditions, such as inflamed tonsils and noninfected and CMV-infected uterine decidual samples, and from transporter-associated processing antigen 2-deficient patients. This in vivo analysis revealed that proinflammatory, but not immune-suppressive, microenvironmental requirements can selectively dictate upregulation of T cell-activating molecules on NK cells. Taken together, these observations offer new and unexpected insights into the direct interactions between NK and T cells and suggest novel APC-like activating functions for human NK cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15578093      PMCID: PMC529284          DOI: 10.1172/JCI22787

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels.

Authors:  A Shevchenko; M Wilm; O Vorm; M Mann
Journal:  Anal Chem       Date:  1996-03-01       Impact factor: 6.986

Review 2.  Cancer immunotherapy: a treatment for the masses.

Authors:  Joseph N Blattman; Philip D Greenberg
Journal:  Science       Date:  2004-07-09       Impact factor: 47.728

3.  The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic.

Authors:  Guido Ferlazzo; Dolca Thomas; Shao-Lee Lin; Kiera Goodman; Barbara Morandi; William A Muller; Alessandro Moretta; Christian Münz
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

4.  The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46.

Authors:  Tal I Arnon; Hagit Achdout; Niva Lieberman; Roi Gazit; Tsufit Gonen-Gross; Gil Katz; Ahuva Bar-Ilan; Noga Bloushtain; Marianna Lev; Aviva Joseph; Eli Kedar; Angel Porgador; Ofer Mandelboim
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

5.  CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro.

Authors:  Simon Rothenfusser; Veit Hornung; Maha Ayyoub; Stefanie Britsch; Andreas Towarowski; Anne Krug; Anja Sarris; Norbert Lubenow; Daniel Speiser; Stefan Endres; Gunther Hartmann
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

6.  The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients.

Authors:  Gal Markel; Huda Mussaffi; Khoon-Lin Ling; Mariolina Salio; Stephan Gadola; Guy Steuer; Hannah Blau; Hagit Achdout; María de Miguel; Tsufit Gonen-Gross; Jacob Hanna; Tal I Arnon; Udi Qimron; Ilan Volovitz; Lea Eisenbach; Richard S Blumberg; Angel Porgador; Vincenzo Cerundolo; Ofer Mandelboim
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

7.  Priming of naive T cells inside tumors leads to eradication of established tumors.

Authors:  Ping Yu; Youjin Lee; Wenhua Liu; Robert K Chin; Jing Wang; Yang Wang; Andrea Schietinger; Mary Philip; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2004-01-04       Impact factor: 25.606

8.  Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors.

Authors:  Pascale André; Roberta Castriconi; Marion Espéli; Nicolas Anfossi; Tiffany Juarez; Sophie Hue; Holli Conway; François Romagné; Alessandra Dondero; Marina Nanni; Sophie Caillat-Zucman; David H Raulet; Cristina Bottino; Eric Vivier; Alessandro Moretta; Pascale Paul
Journal:  Eur J Immunol       Date:  2004-04       Impact factor: 5.532

9.  A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing.

Authors:  M Cella; C Döhring; J Samaridis; M Dessing; M Brockhaus; A Lanzavecchia; M Colonna
Journal:  J Exp Med       Date:  1997-05-19       Impact factor: 14.307

10.  T cell receptor engagement leads to phosphorylation of clathrin heavy chain during receptor internalization.

Authors:  Victoria L Crotzer; Allan S Mabardy; Arthur Weiss; Frances M Brodsky
Journal:  J Exp Med       Date:  2004-04-05       Impact factor: 14.307

View more
  45 in total

1.  Natural killer-cell differentiation by myeloid progenitors.

Authors:  Bartosz Grzywacz; Nandini Kataria; Niketa Kataria; Bruce R Blazar; Jeffrey S Miller; Michael R Verneris
Journal:  Blood       Date:  2010-12-20       Impact factor: 22.113

Review 2.  Human dendritic cell subsets for vaccination.

Authors:  Peter Dubsky; Hideki Ueno; Bernard Piqueras; John Connolly; Jacques Banchereau; A Karolina Palucka
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

Review 3.  Innate lymphocyte and dendritic cell cross-talk: a key factor in the regulation of the immune response.

Authors:  A Reschner; P Hubert; P Delvenne; J Boniver; N Jacobs
Journal:  Clin Exp Immunol       Date:  2008-03-10       Impact factor: 4.330

4.  CD11c identifies a subset of murine liver natural killer cells that responds to adenoviral hepatitis.

Authors:  Bryan M Burt; George Plitas; Jennifer A Stableford; Hoang M Nguyen; Zubin M Bamboat; Venu G Pillarisetty; Ronald P DeMatteo
Journal:  J Leukoc Biol       Date:  2008-07-29       Impact factor: 4.962

5.  Tolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE.

Authors:  Eduardo Huarte; Agnieszka Rynda-Apple; Carol Riccardi; Jerod A Skyberg; Sarah Golden; Maryclare F Rollins; Andrew G Ramstead; Larissa O Jackiw; Massimo Maddaloni; David W Pascual
Journal:  J Autoimmun       Date:  2011-10-22       Impact factor: 7.094

6.  Possible role of natural killer cells in pemphigus vulgaris - preliminary observations.

Authors:  J N H Stern; D B Keskin; N Barteneva; J Zuniga; E J Yunis; A R Ahmed
Journal:  Clin Exp Immunol       Date:  2008-03-28       Impact factor: 4.330

7.  Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4.

Authors:  Jeffrey M Milush; Brian R Long; Jennifer E Snyder-Cappione; Amedeo J Cappione; Vanessa A York; Lishomwa C Ndhlovu; Lewis L Lanier; Jakob Michaëlsson; Douglas F Nixon
Journal:  Blood       Date:  2009-10-05       Impact factor: 22.113

Review 8.  Formation and function of the lytic NK-cell immunological synapse.

Authors:  Jordan S Orange
Journal:  Nat Rev Immunol       Date:  2008-09       Impact factor: 53.106

9.  Human NK cells licensed by killer Ig receptor genes have an altered cytokine program that modifies CD4+ T cell function.

Authors:  Lin Lin; Chao Ma; Bo Wei; Najib Aziz; Raja Rajalingam; Susy Yusung; Henry A Erlich; Elizabeth A Trachtenberg; Stephan R Targan; Dermot P B McGovern; James R Heath; Jonathan Braun
Journal:  J Immunol       Date:  2014-06-16       Impact factor: 5.422

10.  Both conventional and interferon killer dendritic cells have antigen-presenting capacity during influenza virus infection.

Authors:  Corine H GeurtsvanKessel; Ingrid M Bergen; Femke Muskens; Louis Boon; Henk C Hoogsteden; Albert D M E Osterhaus; Guus F Rimmelzwaan; Bart N Lambrecht
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.